News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amgen (AMGN)'s First Quarter 2013 Revenues Increased 5 Percent to $4.2 Billion and Adjusted Earnings Per Share (EPS) Increased 22 Percent to $1.96


4/24/2013 6:36:30 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

THOUSAND OAKS, Calif., April 23, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2013. Key results for the quarter include:

-- Total revenues increased 5 percent to $4,238 million, with 6 percent product sales growth driven by Enbrel(R) (etanercept), XGEVA(R) (denosumab) and Prolia(R) (denosumab).

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
Amgen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES